Table 1

Baseline patient characteristics

Overall patients
Patients number688
Age (years)78 (69–84)
Gender (male)429 (62)
BMI (kg/m²)22.5 (20.2–25.4)
NYHA class
Class III296 (43)
Class IV311 (45)
Ischaemic232 (34)
Non-ischaemic172 (25)
Valvular98 (14)
Hypertensive149 (22)
Others37 (5)
Hypertension490 (71)
Atrial fibrillation345 (50)
Diabetes mellitus250 (36)
Vital signs and others on admission
Systolic blood pressure (mm Hg)120 (105–138)
Diastolic blood pressure (mm Hg)68 (58–81)
Heart rate (bpm)77 (66–92)
LVEDD (mm)56 (48–64)
LVESD (mm)44 (34–54)
LVEF (%)35 (24–55)
E/e′14.4 (10.6–19.4)
eLVEDP (mm Hg)20.5 (18.3–23.5)
Laboratory data
BNPad (pg/mL)671 (370–1170)
BNPdis (pg/mL)280 (153–468)
eGFR (mL/min/1.73 m2)46 (30–60)
BUN (mg/dL)24 (18–34)
Hb (g/dL)12.2 (10.7–13.4)
Hct (%)37 (33–41)
CRP (mg/dL)0.35 (0.12–1.20)
WCC (×103/uL)6.4 (5.1–8.0)
T-Cho (mg/dL)154 (130–178)
HDL-C (mg/dL)42 (34–51)
LDL-C (mg/dL)88 (70–110)
On admission
ACEi or ARB283 (41)
Beta-blockers401 (58)
Aldosterone antagonists186 (27)
Loop diuretics418 (61)
Dobtamin68 (10)
At discharge
ACEi or ARB516 (75)
Beta-blockers539 (78)
Aldosterone antagonists297 (43)
Loop diuretics585 (85)
Median observation period (days)623 (188–730)
  • Values are the median (IQR) and patients number, n (%).

  • ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNPad, circulating B-type natriuretic peptide levels on admission; BNPdis, circulating B-type natriuretic peptide levels at hospital discharge; BUN, blood urea nitrogen; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; eLVEDP, estimated left ventricular end-diastolic pressure; Hb, haemoglobin; Hct, haematocrit; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NYHA, New York Heart Association; T-cho, total cholesterol; WCC, white cell count.